Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
First Claim
Patent Images
1. A multivesicular liposome, comprising:
- a) a neutral lipid;
an amphipathic lipid; and
a hyaluronan-degrading enzyme, wherein the concentration of the hyaluronan-degrading enzyme is between or about between 0.1 mg/mL to 1 mg/mL;
orb) a neutral lipid;
an amphipathic lipid;
a hyaluronan-degrading enzyme; and
hyaluronic acid in an amount sufficient to increase the enzymatic activity of the hyaluronan-degrading enzyme.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.
177 Citations
72 Claims
-
1. A multivesicular liposome, comprising:
-
a) a neutral lipid; an amphipathic lipid; and a hyaluronan-degrading enzyme, wherein the concentration of the hyaluronan-degrading enzyme is between or about between 0.1 mg/mL to 1 mg/mL;
orb) a neutral lipid; an amphipathic lipid; a hyaluronan-degrading enzyme; and hyaluronic acid in an amount sufficient to increase the enzymatic activity of the hyaluronan-degrading enzyme. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 61, 62, 63, 64, 65, 66, 67, 68, 70)
-
-
9. A multivesicular liposome, comprising:
-
a) a neutral lipid; an amphipathic lipid; and a hyaluronan-degrading enzyme, wherein the concentration of the hyaluronan-degrading enzyme is between or about between 0.1 mg/mL to 1 mg/mL;
orb) a neutral lipid; an amphipathic lipid; a hyaluronan-degrading enzyme; and hyaluronic acid in an amount sufficient to increase the enzymatic activity of the hyaluronan-degrading enzyme, wherein the hyaluronan-degrading enzyme is modified by conjugation to a polymer. - View Dependent Claims (10)
-
-
43. A composition, comprising:
-
a hyaluronan-degrading enzyme, wherein the concentration of the hyaluronan-degrading enzyme is at least 50 U/mL; and hyaluronic acid, whereby the hyaluronan-degrading enzyme retains at least 50% of the hyaluronidase activity for at least six months at 28°
C. to 32°
C. or at least one year at 2°
C. to 8°
C. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)
-
-
69. A multivesicular liposome, comprising:
-
a neutral lipid; an amphipathic lipid; and a hyaluronan-degrading enzyme, wherein the concentration of the hyaluronan-degrading enzyme is between or about between 0.1 mg/mL to 1 mg/mL.
-
-
71. A multivesicular liposome, made by a process or obtainable by a process comprising the steps of:
-
a) forming a first aqueous component comprising a hyaluronan degrading enzyme in a concentration less than 2 mg/mL; b) forming a lipid component comprising at least one organic solvent, at least one amphiphatic lipid and at least one neutral lipid; c) forming an emulsion from the first aqueous component and the lipid component; d) dispersing the emulsion into a second aqueous component to form solvent spherules; and e) removing the organic solvent from the solvent spherules to form multivesicular liposomes suspended in the second aqueous component. - View Dependent Claims (72)
-
Specification